, The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study, Ann Rheum Dis, vol.73, pp.1323-1353, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01809208
, White paper: osteoarthritis and mortality iPD meta-analysis. in: Osteoarthritis Research society international (OaRsi) white paper: osteoarthritis: a serious disease. submitted to the U.s. Food and Drug administration December 1, p.28, 2016.
, eUlaR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis, Ann Rheum Dis, vol.77, pp.797-807, 2018.
, College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee, Arthritis Care Res, vol.64, pp.465-74, 2012.
, White paper: osteoarthritis: a serious disease. submitted to the U.s. Food and Drug administration, p.28, 2016.
, 6 national institute for Health and Care excellence. Osteoarthritis. Care and management in adults, 2014.
, nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management, J Neurochem, vol.124, pp.276-89, 2013.
, angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis, Rheumatology, vol.49, pp.1852-61, 2010.
, a systematic review of the efficacy and general safety of antibodies to nGF in the treatment of Oa of the hip or knee, Osteoarthritis Cartilage, vol.23, pp.8-17, 2015.
, When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program, Arthritis Rheumatol, vol.68, pp.382-91, 2016.
, From the cover: evaluation of the effects of tanezumab, a monoclonal antibody against nerve growth factor, on the sympathetic nervous system in adult cynomolgus monkeys (Macaca fascicularis): a stereologic, histomorphologic, and cardiofunctional assessment, Toxicol Sci, vol.158, pp.319-352, 2017.
, Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the american Rheumatism association, Arthritis Rheum, vol.29, pp.1039-1088, 1986.
, The american College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip, Arthritis Rheum, vol.34, pp.505-519, 1991.
, Radiological assessment of osteo-arthrosis, Ann Rheum Dis, vol.16, pp.494-502, 1957.
, Clinical evaluation of the WOMaC 3.0 Oa index in numeric rating scale format using a computerized touch screen version, Osteoarthritis Cartilage, vol.10, pp.479-81, 2002.
, Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (nGF-ab) program with a focus on eligibility assessment, 17 international Conference on Harmonisation, vol.47, p.28, 1994.
, The current status of imaging in anti-nGF clinical trials, Osteoarthritis Cartilage, vol.23, pp.3-7, 2015.
, Variables influencing neuropathic endpoints: the Rochester Diabetic neuropathy study of Healthy subjects, Neurology, vol.45, pp.1115-1136, 1995.
, assessing autonomic dysfunction in early diabetic neuropathy: the survey of autonomic symptoms, Neurology, vol.76, pp.1099-105, 2011.
, Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase iii trial, J Pain, vol.13, pp.790-798, 2012.
, Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase iii trial, Arthritis Rheum, vol.65, pp.1795-803, 2013.
, Graphical approaches for multiple comparison procedures using weighted Bonferroni, simes, or parametric tests, Biom J, vol.53, pp.894-913, 2011.
, examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials, Ann Rheum Dis, vol.75, pp.1964-70, 2016.
, The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials, Ann Rheum Dis, vol.67, pp.1716-1739, 2008.
, Vignon eP, et al. a systematic review of the association between radiographic and clinical osteoarthritis of hip and knee, Osteoarthritis Cartilage, vol.19, pp.768-78, 2011.
, Radiographic knee osteoarthritis and knee pain: cross-sectional study from five different racial/ethnic populations, Sci Rep, vol.8, p.1364, 2018.
, interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: iMMPaCT recommendations, J Pain, vol.9, pp.105-126, 2008.
, Responder analyses and the assessment of a clinically relevant treatment effect, Trials, vol.8, p.31, 2007.
, senn s. statistical pitfalls of personalized medicine, Nature, vol.563, pp.619-640, 2018.
, Van inwegen R. a review of the use of the number needed to treat to evaluate the efficacy of analgesics, J Pain, vol.16, pp.116-139, 2015.
, The cost of dichotomising continuous variables, BMJ, vol.332, p.1080, 2006.
, Statistical power analysis for the behavioral sciences, 1988.
, effect of Tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee, JAMA, vol.322, pp.37-48, 2019.
, efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen, J Rheumatol, vol.41, pp.2249-59, 2014.